NASDAQ: AKBA Akebia Therapeutics Looks Strong, But Risks are Also There
NASDAQ: AKBA Akebia Therapeutics Inc Stock Akebia’s key item being developed is Vadadustat, orally regulated inhibitor of hypoxia-initiating component prolyl hydroxylase (HIF-PH) protein which is being tried in two Phase 3 trials in non-DD, CKD […]